Major companies such as Crinetics Pharmaceuticals, Aquestive Therapeutics, and others are developing potential drug candidates to improve the Carcinoid Syndrome treatment scenario.
Octreotide (Sandostatin) injections are the backbone for symptomatic management of Carcinoid Syndrome. Xermelo (telotriastat ethyl) tablets combined with
somatostatin analog (SSA) therapy is FDA approved for treating Carcinoid Syndrome adults.
In May 2021, Crinetics Pharmaceuticals announced financial results for the first quarter ended March 31, 2021, and provided a corporate update. Crinetics mentions that it had plans to advance paltusotine into a Phase II trial to treat carcinoid syndrome associated with neuroendocrine tumors.
Get an overview of pipeline landscape @
Carcinoid Syndrome is the array of symptoms that occur secondary to carcinoid tumors. The disease is seen in individuals who have an underlying carcinoid tumor that spreads to the liver. Carcinoid Syndrome treatment involve
Bavarian Nordic, BioCryst Pharmaceuticals, Integrated Biotherapeutics, Geovax, Batavia Biosciences,
Globavir Biosciences, Collaboration Pharmaceuticals, Emergex Vaccines, ReiThera, Emergent BioSolutions, Mapp Biopharmaceuticals, Biofactura, Alkido Pharma, Flow Pharma, and others are developing potential drug candidates to improve the Marburg Virus Disease treatment scenario.
BioCryst is developing
galidesivir in partnership with U.S. government agencies and other institutions. In September 2013, the National Institute of Allergy and Infectious Diseases (NIAID) contracted with BioCryst to develop galidesivir to treat Marburg virus disease and potentially for other filoviruses, including the Ebola virus.
Integrated BioTherapeutics Inc. (IBT), in May 2021, announced the receipt of a contract valued at up to USD 16.3 million from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to develop IBT-T03H, a monoclonal an
Alzheimer’s Disease pipeline shows progress in the clinical trials with the upcoming therapies such as BAN2401, Gantenerumab, Bryostatin-1, INB03, AZT-211,.
Glioblastoma Pipeline Analysis: 60+ Key Pipeline Therapies and 60+ Key Pharma Players are Looking Out in the Glioblastoma Pipeline Landscape
iCrowd Newswire
DelveInsight s
Glioblastoma Pipeline Insight report offers a detailed overview of the pipeline therapies that are in various clinical and preclinical stages of growth, as well as their launch and how the market is expected to change as a result across the Glioblastoma domain.
For Glioblastoma emerging drugs, the Glioblastoma Pipeline Analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA.
The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.